Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novo Nordisk A/S
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study.
Male or female, age 18 years or older at the time of signing informed consent.
Type 2 diabetes mellitus diagnosis.
Treatment with either 1 or 2 oral antidiabetic medications.
Current member of a commercial or Medicare health plan with pharmacy benefits.
Recorded HbAlc value within the last 90 days prior to randomization.
Further intensification with an additional antidiabetic oral or injectable medication is indicated to achieve glycemic target at the discretion of the study physician according to approved labelling.
You may not be if
Previous randomization in this study
Treatment with more than 2 oral antidiabetic medications, oral semaglutide, or any injectable medication in a period of 30 days before the day of eligibility assessment. Temporary/emergency use of any type of insulin is allowed, as is prior insulin treatment for gestational diabetes.
Contraindications to semaglutide according to the Food and Drug Administration approved label.
Female who is pregnant, breastfeeding or intends to become pregnant
Participation in another clinical trial.
Clareo Health | Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
